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Aims: We investigated the relationship between arrhythmia burden, left atrial volume (LAV) 
and N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) at baseline and after long-term 
follow-up of atrial fibrillation (AF) ablation. 
Methods: We studied 38 patients (23 paroxysmal, six women, mean age 56±11) scheduled 
for AF ablation. LAV was calculated on the basis of computed tomography images at baseline 
and long-term follow-up, and arrhythmia burden was graded from self-reported frequency and 
duration of AF episodes.  
Results: After a mean period of 22±5 months, 28/38 patients (11/15 persistent) were free 
from AF recurrence. At baseline there were no differences in mean LAV (125 vs. 130 cm3, 
p=0.7) or median NT-pro-BNP (33.5 vs. 29.5 pmol/L, p=0.9) between patients whose ablation 
had been successful or otherwise. At long-term follow-up there was a marked decrease in 
LAV (105 vs. 134 cm3, p<0.05) and level of NT-pro-BNP (7 vs. 17.5 pmol/L, p<0.05) in the 
successful ablation patients. NT-pro-BNP correlated with LAV both at baseline (r=0.71, 
p<0.001) and at follow-up (r=0.57, p<0.001). Arrhythmia burden correlated with both NT-
pro-BNP (r=0.47, p<0.01) and LAV (r=0.52, p<0.01). A decrease in NT-pro-BNP at follow-
up of > 25% of baseline value had a specificity of 0.89 and a sensitivity of 0.6 (receiver 
operator characteristics, accuracy 0.82) for ablation success. 
Conclusions: NT-pro-BNP correlates with LAV and arrhythmia burden in AF patients and 
both NT-pro-BNP and LAV decrease significantly after successful ablation. A decrease in 
NT-pro-BNP of >25% from the baseline value could be useful as a marker of ablation 
success. 
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Introduction 
Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice, and 
pulmonary vein (PV) isolation by radiofrequency ablation (RFA) has become the standard 
therapy for selected patients [1]. In paroxysmal AF, quite high success rates are reported with 
isolation of the PVs only [2], but in persistent and permanent AF extended ablation strategies 
may be required [3-4]. Triggers seem to be important for initiation of AF, but an 
arrhythmogenic substrate appears to be necessary for the perpetuation of long-lasting AF 
episodes [5-6]. Electro-anatomical remodelling of the atrial tissue leads to changes in atrial 
conduction, shortening of refractory period and atrial dilatation [7]. The increase in atrial size 
is correlated with the degree of atrial fibrosis [8] and may be used as a measure of the atrial 
remodelling process.   
AF also causes changes in the endocrine functions of the atria, and AF patients have higher 
levels of natriuretic peptides [9-11]. Plasma N-terminal pro-B-type natriuretic peptide (NT-
proBNP) correlates with left atrial (LA) size [12] and epidemiological studies have identified 
it as a predictor of the development of AF [13]. Successful ablation of AF may initiate a 
reverse remodelling process in the atria, and LA size and NT-proBNP may decrease after 
restoration of sinus rhythm [14-17]. 
In this study we aimed to investigate the relation between arrhythmia burden, left atrial size 
and NT-proBNP before AF ablation and after long-term follow-up in patients with normal left 
ventricular systolic function. 
Methods 
Patient characteristics 
Thirty-eight consecutive patients with drug-refractory paroxysmal, persistent or longstanding 
persistent AF were included in the study. Demographics and clinical data were collected prior 
to the procedure (Table 1). Self-reported AF burden was graded according to a modified 
arrhythmia frequency and severity scale [18], with 1-10 points for each frequency and 
duration of AF episodes (range 2-20). They underwent their first electrophysiological study 
and RFA during the second half of 2007, and further procedures if necessary. Patients with 
impaired systolic heart function (left ventricular ejection fraction < 50%), renal failure 
(glomerular filtration rate < 60ml/min) or valvular diseases were excluded. At the end of the 
study patients were divided into two groups, with successful ablation or recurrence of AF. All 
patients provided written informed consent. The study was performed in accordance with the 
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Declaration of Helsinki, and was approved by the local ethics committee (Regional Ethics 
Committee of Western Norway).
Electrophysiological study and ablation procedure 
Patients underwent electrophysiological study and RFA in a fasting, sedated state. Vascular 
access was obtained under local anaesthesia through the right and left femoral veins. In all 
patients, a 7F 20-pole steerable mapping catheter (Livewire™, St. Jude Medical Inc, St. Paul,
MN) was positioned in the coronary sinus, looped around the tricuspid annulus. After 
transseptal puncture, a 10-pole circular mapping catheter (Lasso™, Biosense Webster, 
Diamond Bar, CA, USA or Optima™, St. Jude Medical Inc) was introduced into the LA 
through an 8.5F transseptal introducer.  An irrigated RFA catheter (ThermoCool®, Biosense 
Webster or Navistar® ThermoCool, Biosense Webster) was advanced into the LA through the 
same puncture site without a second introducer. A three-dimensional mapping system (Ensite 
NavX™ (St. Jude Medical Inc.) or Carto™XP (Biosense Webster)) was employed to guide 
mapping and ablation.  
All 38 patients underwent electrical isolation of all PVs, confirmed by a circular mapping 
catheter. Twenty-one patients underwent PV isolation only. The remainder were given 
additional ablation of the cavotricuspid isthmus line (n=2), mitral isthmus line and one line 
connecting the two superior veins (n=4), ablation on complex fractionated atrial electrograms 
(CFAE, n=6), or a combination of the approaches (n=5) at the operator’s discretion. The RFA 
application time was 40-60 seconds at each site and energy was delivered with a cut-off 
temperature of 50˚ C. The maximum output and irrigation rates were 30-35 W, 15-20 mL/min 
(for PV isolation) and 30-40 W, 20 mL/min for linear or CFAE ablation (maximum 35 W in 
LA, 40 W in right atrium (RA)), respectively. A Stockert-Cordis (Biosense Webster) RFA 
generator was utilized.  
Blood sampling  
Blood samples from the antecubital vein were obtained in all patients one day before ablation, 
and again on the long-term follow-up visit. NT-proBNP was determined using an 
electrochemiluminescence immunoassay on a Modular E system (Roche Diagnostics, 
Mannheim, Germany). The analytical detection limit was 1 pmol/L. 
Computed tomography (CT) 
All patients underwent cardiac CT imaging on the day before the ablation procedure and at 
the final follow-up. Imaging was performed with a 64-slide scanner (Aquillion 64, Toshiba, 
Jpn) with or, in patients in AF during imaging, without ECG-gated techniques. We acquired 
data during one breath-holding, which began after a bolus injection of contrast (Iomeron 
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400mg I/mL).  For ECG-gated images, we used 0.5 mm and for non-gated images 1.0 mm 
slide thickness.  
LA three-dimensional reconstructions and calculations of LA volumes were performed using 
an automated algorithm in the Ensite NavX™ Verismo system (St. Jude Medical Inc.). Before 
the calculation of chamber volume, the pulmonary veins were excluded at the ostia. The LA 
auricle could not be reconstructed in all patients, and was therefore also excluded [19]. 
Follow-up 
Patients were followed up as out-patients at our clinic or by their local hospitals and referring 
cardiologists. All patients underwent clinical examination and at least one Holter registration 
at three and six months after the procedure. Additional clinical examination was performed if 
indicated by symptoms. Recurrence was defined as more than one episode of AF lasting more 
than 30 seconds after a one-month blanking period. At the end of follow-up all patients were 
examined at our clinic with a further seven days of heart rhythm monitoring using a specially 
developed event recorder for AF detection (AF Alarm, Medtronic, MN), CT imaging and 
blood sampling.  
Statistical analysis 
For all statistical analyses the SPSS software package version 17.0 (SPPS Inc., IL, USA) was 
used. Discrete variables are reported as counts (percentages) and continuous variables as 
mean ± SD or median and range for non-normal distributed data. Statistical comparisons were 
performed using the 2 or Fisher exact test for discrete variables. Continuous variables were 
assessed for characteristics of distribution by use of the Kolmogorov-Smirnov test and NT-
pro-BNP was identified as non-normal distributed. Comparisons were performed using 
Student’s t-test for parametric data and Mann-Whitney-U test for non-parametric data. 
Correlations were calculated using linear regression analysis and Spearman’s rank correlation 
tests. A p-value of <0.05 was considered to be statistically significant. A receiver operator 
characteristic curve and best cut-off were calculated and plotted using R version 2.12.0 (The 
R Foundation for Statistical Computing, Austria). 
Results 
Clinical and procedural data 
Demographics and procedural data are shown in Table 1. There were no differences in the 
distribution of co-morbidity, pre-procedural echocardiography data or procedure time in the 
two groups. There were more women in the AF recurrence group; otherwise the demographic 
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data were similar. At baseline, 23 (60%) patients were regarded as paroxysmal, 4 (11%) as 
persistent and 11 (29%) as longstanding persistent AF. All patients had tried at least one anti-
arrhythmic drug at referral, but none were still using amoidarone. Mean AF burden was 13.7 
± 4.4 before ablation. One patient in the success group had a minor, asymptomatic PV 
narrowing (approximately 30% based on the CT reconstruction) at follow-up.  No other 
procedure-related complications, such as cardiac tamponade, atrio-esophageal fistula or major 
bleeding were observed in any of the patients. 
Clinical follow-up 
At mean follow-up of 22 ± 5 months, fourteen patients (37%) had undergone an additional 
ablation procedure because of recurrence of AF, and the mean number of procedures 
performed per patient was 1.4 ± 0.5 (1.3 for paroxysmal and 1.6 for persistent AF, p=0.09). 
Anti-arrhythmic drugs were continued in all patients at least three months after ablation and 
then discontinued if freedom of AF. After the last procedure the mean follow-up time was 17 
± 7 months. At the end of the study, 28/38 patients (74%) (11/15 persistent/longstanding 
persistent – 73%) were free of AF recurrence, while two (one paroxysmal and one persistent 
AF) were still on anti-arrhythmic drugs. One patient with longstanding persistent AF at 
baseline was still in continuous but asymptomatic AF. Two patients with late recurrence of 
AF were scheduled for new ablation procedures. The remaining seven patients with 
recurrence experienced a lower AF burden and a better quality of life, and by the time of 
follow-up had not been referred for new procedures. 
Natriuretic peptides and atrial size 
Baseline median NT-pro-BNP for all patients was 32.0 (range 2-179) pmol/L and 
demonstrated a statistically significant decrease at long-term follow-up (9.5, range 1-127 
pmol/L, p< 0.001). Mean left atrial volume was 126.4 ± 35.7 mL at baseline and fell to 113.5 
± 33.5 pmol/L after ablation, p< 0.001. There were no differences in mean atrial volume or 
NT-pro-BNP between patients with or without successful ablations at baseline, but at long-
term follow-up there was a marked decrease in atrial volume and level of pro-BNP only in 
those whose ablation had been successful (Figure 1). NT-pro-BNP correlated with atrial 
volume at both baseline (y=0.79x – 61, r=0.71, p<0.001) and at follow-up (y=0.43x – 31, 
r=0.57, p<0.001).  
There was also a small and statistically significant decrease in the anterior-posterior diameter 
of the LA after ablation (40.1 ± 5.9 vs. 41.7 ± 7.1 mm, p=0.03), but the difference between 
patients whose ablation had or had not been successful was not statistically significant (39.1 ± 
6.1 vs. 42.6 ± 3.4 mm, p=0.15).  
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A decrease in the level of NT-pro-BNP at follow-up indicated successful ablation. The area 
under the curve for percentage reduction in NT-pro-BNP was 0.805 (Figure 2) and the best 
cut-off for percentage NT-pro-BNP reduction by maximizing accuracy was -25% (accuracy  
0.82, sensitivity 0.6 and specificity 0.89); by minimizing distance from perfect classification it 
was -50% (accuracy 0.71, sensitivity 0.8, specificity 0.68).
The self-reported AF burden correlated with both NT-pro-BNP (r=0.47, p<0.01) and atrial 
volume (r=0.52, p<0.01) at baseline. When patients were stratified for AF burden, statistically 
significant increases in atrial volume and NT-proBNP were demonstrated with increasing AF 
burden (Figure 3).  
Discussion 
We measured the levels of NT-pro-BNP and LA volume at baseline and long-term follow-up 
after RFA for AF. Our findings demonstrate a correlation between self-reported arrhythmia 
burden, LA volume and NT-pro-BNP at baseline. At long-term follow-up there was a marked 
decrease in LA volume and NT-pro-BNP in patients whose ablation had been successful. 
Those with recurrence of AF showed no such differences.  
NT-pro-BNP 
NT-pro-BNP is the inactive, more stable pro-hormone of B-type natriuretic peptide. Hwang et 
al [12] showed that the measurement of NT-pro-BNP added incremental predictive value to 
LA size and diastolic function before AF ablation. In patients with preserved left ventricular 
systolic function, AF and LA size have been shown to be independent predictors of NT-
proBNP [10, 20]. In our study, baseline values of NT-pro-BNP and LA size (including 
volume and echocardiographic LA diameter) did not differ in patients whose ablation had or 
had not been successful. The heart rhythm was not systematically recorded at the time of 
blood sampling. In patients with a resent onset of AF before blood sampling, this might have 
increased the measured NT-pro-BNP level. In accordance with previous studies [16, 21-22], 
baseline NT-pro-BNP values decreased significantly in patients after successful restoration of 
sinus rhythm. Patients with recurrence of AF had no significant reduction in median NT-pro-
BNP after ablation. Some recurrent AF patients yet had a major reduction in AF burden after 
ablation, which might contribute to a reduction in NT-pro-BNP. We included patients with 
paroxysmal AF and relatively low AF burden (mean 13.7/20; range 8-20). Several of these 
patients had a baseline NT-pro-BNP well within the normal range, yet there was a statistically 
significant decrease of NT-pro-BNP in patients after successful ablation which correlated 
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with the reduction in LA volume. Measurement of NT-pro-BNP at baseline and follow-up 
may therefore add value to the clinical evaluation of ablation success. NT-pro-BNP measured 
before ablation was not identified as a valid predictor of ablation outcome. 
CT imaging 
We used an automated algorithm based on three-dimensional co-ordinates from the 
reconstructions of the cardiac CT to calculate LA volumes. This method has not previously 
been published in studies of this type. The normal standard for calculating LA volume 
involves manually tracing each cross-sectional image of the CT scan [23]. The automated 
approach used in our study revealed a close correlation to this method. In clinical practice, LA 
diameter measured by echocardiography is the most widely used method of measurement , 
but Hof et al found a poor correlation between LA diameter and LA volume as measured 
using CT [24]. In our study, the difference in LA size between successful or unsuccessful 
ablated patients was only significant using atrial volumes, not LA diameters. 
Atrial size 
AF causes atrial remodelling and leads to enlargement of the atria [5-6]. These processes may 
be reversible. A reverse remodelling process takes place after successful restoration of sinus 
rhythm [25-26]. Reant et al described an improvement in left ventricular systolic and diastolic 
function and a decrease in LA size measured by echocardiography after catheter-based 
ablation [26]. In patients with recurrent AF, increases in LA dimensions have been shown 
[27], but our study does not reproduce this finding. Some of our patients whose ablation was 
unsuccessful experienced a marked decrease in AF burden, which may have influenced the 
degree of LA dilatation. Previous studies have demonstrated that a larger LA predicts worse 
outcome after AF ablation, that pre-procedural measurements of LA volume may be useful to 
identify patients for ablation restricted to PV isolation, and that patients with larger LA 
volumes need additional ablation [28]. Our study did not identify pre-ablation LA size as a 
valid predictor of ablation outcome. 
The decrease in atrial size may be caused in part by the formation of atrial scars after ablation. 
Such scar formation should also occur in patients with recurrence of AF after ablation. 
Neither the total ablation time nor the proportion of patients with ablation additional to PV 
isolation were different in patients with or without AF recurrence in this study. It might 
therefore be reasonable to assume that the main contributor to the reverse remodelling seen 
after ablation is the restoration of sinus rhythm.  
There is evidence that LA size predicts the cardiovascular outcome in a population [29]. 
Thromboembolization from the LA auricle is one of the most important causes of AF-related 
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stroke events. Dilatation and impaired function of the auricle has been associated with 
thrombus formation. Moreover, the LA auricle undergoes reverse remodelling after successful 
AF ablation [30], which could theoretically indicate a decrease in thromboembolic risk after 
ablation. In the present study, the LA auricle was excluded from the volume calculations. 
Further studies of this topic are needed. 
Recurrence of AF 
There were more women in the recurrence group; otherwise there were no differences in 
baseline characteristics in patients with or without AF recurrence. There was a tendency to 
more ablation procedures in patients with successful ablation, but the difference was non-
significant. However, this might indicate that a higher success rate could have been achieved 
with repeated procedures in patients with AF recurrence. Some patients nevertheless 
experience a significant clinical improvement even after ablation that was unsuccessful in 
curing AF. After ablation, asymptomatic AF might be present and twentyfour-hour Holter 
monitoring might not provide a true success rate [31]. All our patients had at least one 
additional seven-day event recording at long-term follow-up and a total of six asymptomatic 
AF episodes were revealed. One recurrent AF patient experienced a purely asymptomatic 
recurrence, other patients with registered asymptomatic episodes had known symptomatic AF. 
Study limitations 
This study was not randomized and patients received a different ablation approach based on 
their type of AF, but the demographical and procedural data were similar in patients whose 
outcomes were or were not successful. Atrial fibrillation during CT imaging excludes an 
ECG-gated technique, and in patients whose rhythms were different at baseline and follow-up 
this might have confounded the results.  
Arrhythmia burden at baseline was based on a self-reported arrhythmia scale. Patients with 
asymptomatic AF episodes might therefore have underestimated their true AF burden. 
Finally, there exists the possibility of measurement bias for volume estimations due to the 
inclusion of parts of the left atrial auricle or the PVs.  
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Conclusions 
NT-pro-BNP correlates with atrial volume and arrhythmia burden in AF patients. Both NT-
pro-BNP and atrial volume decrease significantly after successful ablation, but not in patients 
with recurrence of AF. A decrease in NT-pro-BNP of >25% from the baseline value may be 
useful as a indicator of ablation success. 
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Table 1. Baseline characteristics and procedural data 
Patient characteristics Successful 
ablation 
N = 28 
Recurrence of 
AF 
N = 10 
P- value 
Age (years) 56 ± 12 57 ± 11 0.90 
Female (%) 2 (11) 4 (40)    0.04 * 
Duration of AF (years) 10 ± 7 12 ± 8 0.52 
Number of AADs 1.9 ± 1.0 2.0 ± 0.7 0.85 
Paroxysmal AF (%) 19 (68) 6 (60) 0.47 
AF burden  13.7 ± 3.9 13.7 ± 5.2 0.99 
Hypertension (%) 11 (39) 4 (40) 0.62 
Coronary heart disease (%) 3 (11) 1 (10) 0.72 
Left ventricular ejection fraction (%) 61 ± 6 62 ± 5 0.75 
Echocardiographic left atrial diameter (mm) 43 ± 6 45 ± 7 0.38 
Number of ablation procedures 1.7 ± 0.8 1.2 ± 0.7 0.10 
     PVI only (%)    15 (54) 6 (60) 0.27 
     Procedure time (min) 236 ± 83 213 ± 58 0.42 
     Total ablation time (min) 54 ± 20 47 ± 14 0.33 
AF=Atrial fibrillation, AAD=Anti-arrhythmic drug, PVI=Pulmonary vein isolation. AF 
burden = Self-reported frequency and duration of AF episodes, scored from 2 to 20. 




Median plasma pro-brain natriuretic peptides (NT-pro-BNP) and mean left atrial volume 
(LAV) at baseline (BL) and follow-up (F-U). There were no differences in baseline values in 
patients with or without recurrence of atrial fibrillation (AF). 
Figure 2 
Receiver operator characteristics curve for percentage change in NT-pro-BNP. AUC = area 
under the curve. 
Figure 3 
Baseline median NT-pro-BNP and mean left atrial volume (LAV) in patient tertiles, based on 
self-reported atrial fibrillation burden (AFB) (first tertile AFB < 12, second tertile AFB 12-14, 
third tertile AFB > 15). The differences between the first and second tertile were not 
statistically significant (NT-pro-BNP p=0.14, LAV p=0.07), between the second and third 
tertile there were a statistically significant difference for NT-pro-BNP (p<0.05), but not for 
LAV (p=0.10).  
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